Brief: Onward Medical Receives New FDA Breakthrough Device Designations
23/02/2023 06:35
Feb 23 (Reuters) - Onward Medical NV ONWD.BR :
* ONWARD RECEIVES NEW FDA BREAKTHROUGH DEVICE DESIGNATIONS
FOR
BLADDER CONTROL, ALLEVIATION OF SPASTICITY, AND BLOOD PRESSURE
REGULATION AFTER SPINAL CORD INJURY
* ONWARD IS NOW PREPARING REGULATORY SUBMISSIONS FOR U.S.
AND
EUROPE, WITH EXPECTATION THAT THIS THERAPY MAY BE APPROVED FOR
COMMERCIALIZATION IN LATE 2023
Source text for Eikon: ID:nGNE1MVy5d
Further company coverage: ONWD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on ONWARD Medical
See all newsBrief: Onward Medical Primary ABB Final Deal Size Was C.Eur 50m / 11.3m Shares, Says Bookrunner
Brief: Ottobock Invests EUR 10 Million In Onward Medical
Brief: Bookrunner Says Onward Medical Primary ABB Books Covered, Further Guidance To Follow
Brief: ONWARD Medical Receives FDA De Novo Classification
Brief: Onward Medical Says Receives FDA De Novo Classification And US Market Authorization For ARC-EX System